hotspot -WSS

hotspot

author：explore 2025-09-03 15:20:24 - browse：386

An orange Flovent inhaler on a white background. -- health coverage from STAT — Adobe

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years.

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as fluticasone.

The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be able to avoid paying a penalty.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

WSS

CDC recommends RSV monoclonal antibody for infants

Key House Republican on health care plans exit from Congress

'Revelatory' study finds a smoking impact that remains after quitting

H.R. 3 is the wrong path to lower drug costs

Medicare Advantage proposed rates disappoint insurers

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

focus

hotspot

leisure time

Heart attack and stroke risk calculators need revising

Heart disease in astronauts blamed on cosmic radiation

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

In age of alternative facts, a scholarly course on calling out crap

The dental labor crisis is a moment of opportunity

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

For Medicare Advantage, Democrats want stronger protections around AI

Moonlake's readout produced a cash windfall. Risks remain

How digital tools helped lower hypertension in marginalized patients

entertainment

A controversial new treatment promises to make little people taller

FDA scientists endorse Pfizer/BioNTech Covid

Senators start work on Medicare physician payment reform

Physicians aren't 'burning out.' They're suffering from moral injury

Group behind ProMed defends move to subscription

The cancer stories no one wants to hear

focus

knowledge

knowledge

explore